Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) Results Under Cloud

Posted by Lynn Eisler February 6, 2014 0 Comment 1373 views


Ever since the Israel based development stage drug maker Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) reported what it termed as “Successful FDA Phase 2a Clinical Trial Result” for its diabetes pill, its stock has been hammered at the stock exchange. It has shed close to 37 percent of its market valuation during trading last week. During trading on 5th February, the investors paused to dig deeper into the results announcement, and finding hidden positives in the trial result, bought back into the stock in a major bull run. This sent the stock upwards by a substantive 6.7 percent during trading on 5th February.

Management Team Satisfied With Result

At the time of announcement of the trial results, Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) CEO Nadav Kidron had expressed his satisfaction with the test findings and had been quoted to have said that, “We are extremely pleased with the results which give a solid validation for Oramed’s platform technology in general and our oral insulin program in particular .Following on the results from this type 2 diabetes study we are gearing up to start a multi-center Phase 2b study later this year.  We are also excited about the potential of this drug for type- 1 Diabetes and plan to initiate a Phase 2a FDA study for this indication in the near term.”

Cause Of Crash Being Investigated

In related news, law firm Bronstein, Gewirtz & Grossman, LLC announced on 4th February that it was investigating if claims can be made on behalf of the share holders of Oramed Pharmaceuticals Inc. with regards to the sudden crash of the stock price; post the announcement of the phase 2 test results of its diabetes drug. The law firm is specifically investigating if certain of the officers and directors of the drug firm had violated any of their fiduciary duties in the course of this development.



About Lynn Eisler

Lynn Eisler is a national news reporter focusing on economic issues, data analysis and the financial health of state and local governments. Lynn has been honored with the H.L. Mencken Award for Investigative Reporting, the Champion of Justice Award for reporting on the drug war, and the John Hancock Award for business reporting. Lynn was also a Knight Medical School Fellow at the University of Michigan.

View all post by Lynn Eisler Visit author's website

Write Your Comment